FDA has approved Fabhalta® as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria.
Novartis today announced that FDA approved Fabhalta® (iptacopan) as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune…